Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 586.36% and ...

We recently compiled a list of the 10 Best Counter Cyclical and Defensive Stocks to Invest In. In this article, we are going ...

Eli Lilly and Company has announced the FDA approval of EBGLYSS for treating atopic dermatitis in adults and children over 12 ...

Eli Lilly and Company has revealed positive topline results from the Phase III trials of efsitora alfa to treat adults with ...

We recently compiled a list of the 7 Best Big Company Stocks to Buy Now. In this article, we are going to take a look at ...

Thanks for joining us. I'm Terence Flynn, the U.S. Biopharma analyst here at Morgan Stanley. Very pleased to be hosting Eli Lilly this morning. I'm hosting Jake Van Naarden, who is President of Lilly ...

The original concerns of the US regulatory agency over the manufacturing of Eli Lilly’s Ebglyss seem to have been resolved, ...

The company ... Lilly said: 'We recognize that any supply challenge may cause a disruption in people’s treatment regimens, and we are moving with urgency to address it. Anyone experiencing difficulty ...

Discover Citi's bullish outlook on Eli Lilly with a $1,060 target. Is now the time to invest? Find key insights and price ...

Data from the two Phase III trials showed that efsitora induced HbA1C reductions similar to daily insulin in both type 1 and ...

Physicians and health professionals from around the country demanded that Novo Nordisk and Eli Lilly make their novel diabetes and obesity medications affordable and accessible to all.